End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
26,750 KRW | -0.37% | +2.49% | +3.88% |
Apr. 24 | US solar panel makers seek new tariffs to protect domestic factories | RE |
Apr. 17 | US plans to restore tariffs on dominant solar technology, sources say | RE |
Strengths
- Its low valuation, with P/E ratio at 3.38 and 2.65 for the ongoing fiscal year and 2025 respectively, makes the stock pretty attractive with regard to earnings multiples.
- The company shows low valuation levels, with an enterprise value at 35.59 times its sales.
- The company appears to be poorly valued given its net asset value.
- Given the positive cash flows generated by its business, the company's valuation level is an asset.
- Analysts covering this company mostly recommend stock overweighting or purchase.
- The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
- The average price target of analysts who are interested in the stock has been strongly revised upwards over the last four months.
- The opinion of analysts covering the stock has improved over the past four months.
Weaknesses
- The potential for earnings per share (EPS) growth in the coming years appears limited according to current analyst estimates.
- As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
- Low profitability weakens the company.
- For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
- Revenue estimates are regularly revised downwards for the current and coming years.
- For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
- For the last twelve months, the analysts covering the company have given a bearish overview of EPS estimates, resulting in frequent downward revisions.
- Over the past twelve months, analysts' opinions have been revised negatively.
- Prospects from analysts covering the stock are not consistent. Such dispersed sales estimates confirm the poor visibility into the group's activity.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Life & Health Insurance
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+3.88% | 1.45B | B | ||
+14.78% | 79.51B | B- | ||
+6.49% | 50.92B | B+ | ||
+1.35% | 48.11B | B | ||
+6.55% | 39.71B | B+ | ||
+19.34% | 37.78B | B | ||
+2.84% | 30.07B | B | ||
-7.77% | 27.56B | B- | ||
-18.42% | 24.71B | A- | ||
+6.89% | 21.99B | A |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- A000880 Stock
- Ratings Hanwha Corporation